Regulus Therapeutics (RGLS) Tops Q3 EPS by 3c

November 1, 2016 4:11 PM EDT
Get Alerts RGLS Hot Sheet
Trade RGLS Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Regulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.37), $0.03 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $1.2 million.

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings

Related Entities

Earnings

Add Your Comment